INTRODUCTION
The prevalence of intracranial aneurysm is 2% to 3% in the general population, and is more common in patients who experience acute ischemic stroke. [1] [2] [3] Intracranial aneurysms have been considered to be a relative contraindication to the administration of the recombinant tissue plasminogen activator (rtPA) due to the theoretical risk for an aneurysmal rupture in individuals who experience acute ischemic stroke. 4 However, recent studies have not reported an increase in the risk for rtPA-related intracranial hemorrhage in patients with both acute ischemic strokes and intracranial aneurysms. [5] [6] [7] In one prospective multicenter study, the authors provided reassurance that the risk for intracranial hemorrhage does not increase in acute ischemic stroke patients harboring an intracranial aneurysm. 5 The issue of administering rtPA to stroke patients with an intracranial aneurysm is very important because 
CASE REPORT
A 51-year-old man with untreated hypertension present- A B mmHg, and was 169/98 mmHg immediately following the CT angiography. A non-contrast CT, which was performed concurrently with CT angiography, revealed SAH predominantly in the right cerebral convexity and falx ( Fig. 2A, B) .
A CT angiography revealed a saccular aneurysm, 3 mm in size, with a bleb in the right MCA bifurcation and an occlusion of the left MCA M1 portion (Fig. 2C, D) . Five hours later, emergent surgical clipping was performed to secure the ruptured aneurysm.
During the operation, a saccular aneurysm with a bleb in the right MCA bifurcation, which was found out in CT angiography, was also observed. After clipping, a thrombectomy of the left MCA was considered, but ultimately was not performed. It was concluded that it was too risky because of the large ischemic area and the presence of SAH. The next morning, brain swelling in the infarcted hemisphere was observed on a follow-up CT scan and decompressive hemicraniectomy was performed 12 hours after the aneu- was applied for four days due to intracranial hypertension and brain swelling despite hemicraniectomy.
Despite the administration of nimodipine to prevent delayed cerebral infarction, a right MCA territory infarction was detected on a follow-up CT, five days after SAH. However, there were no definitive vasospasms on the conventional angiography (Fig. 3) . On discharge five weeks after initial presentation, the patient was alert but had global aphasia and quadriplegia (modified Rankin score 5). His neurological status remained unchanged one year after being discharged.
DISCUSSION
The patient developed SAH in the right cerebral hemisphere-the contralateral side of the infarction-after administration of rtPA. A CT angiography revealed a saccular aneurysm with a bleb in the right MCA bifurcation. Thus, we believe that the unruptured aneurysm ruptured soon after the infusion of rtPA.
To the best of our knowledge, this is the first report to describe a rupture of an aneurysm in the non-infarcted hemisphere soon after an intravenous infusion of rtPA.
There have been only three case reports describing aneurysmal SAH that developed after the infusion of rtPA. In the first reported case, 8 the patient experienced a thunderclap headache three days before there was a presentation with ischemic stroke. Thus, the patient may have experienced a previous hemorrhage and the re-bleeding was precipitated by rtPA. The second case described a patient with a dissecting aneurysm, 9 which did not suggest that an incidental aneurysm ruptured following the infusion of rtPA. In the third case, a previously concealed thrombosed saccular aneurysm was revealed after recanalization. 10 These reports, In conclusion, the current study demonstrates that an incidental intracranial aneurysm may rupture after an intravenous infusion of rtPA in patients who experience acute ischemic stroke. Although recent studies have demonstrated no increase in the risk for rtPA-related intracranial hemorrhage in acute ischemic stroke patients harboring intracranial aneurysm, we suggest that rupture-prone aneurysms, in terms of size and shape, would be considered as a relative contraindication to rtPA. Future studies are needed to investigate whether rtPA is beneficial or harmful in patients who have both acute ischemic stroke and intracranial aneurysms.
